

Special Issue

Metabolic Reprogramming in Cancer: New Frontiers for Therapeutic Intervention

Message from the Guest Editors

In this Special Issue, we aim to cover the recent progress in cancer therapy by targeting cancer metabolism. We hope to pave the way for innovative and effective therapeutic strategies by addressing the complexities of metabolic plasticity and heterogeneity in cancer cells. The topics include, but are not limited to, the following: (i) Molecular mechanisms underlying metabolic adaptability in therapeutic resistance; (ii) Metabolic heterogeneity in cancer; (iii) Determination of how tumor microenvironment, such as hypoxia and nutrient availability, influence cancer metabolism; (iv) Development of novel therapies and combination strategies to improve therapeutic efficacies and clinical outcomes. We seek original research articles, reviews, and short communications and invite researchers, clinicians, and industry professionals to contribute their insights and findings to advance our understanding of cancer metabolism and its application in clinical practice.

Guest Editors


Dr. Songhua Hu

Dr. Yahui Wang

Dr. Daniel Oscar Cicero

Deadline for manuscript submissions

31 December 2025



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/223420

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).